LKLeena Kämppi

Leena Kämppi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Leena Kämppi has a total of 62 co-authors. Here are the top co-authors by number of shared publications:

  • Harri Mustonen

    Abdominal Center, Department of Gastrointestinal Surgery, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland

    3 shared publications
  • Adam Strzelczyk

    Epilepsy Center Frankfurt Rhine‐Main, Department of Neurology Goethe‐University Frankfurt Frankfurt am Main Germany

    2 shared publications
  • Jaakko Ritvanen

    Department of Neurology Helsinki University Hospital and University of Helsinki Helsinki Finland

    2 shared publications
  • Seppo Soinila

    Division of Clinical Neurosciences/General Neurology, Department of Neurology, Turku University Hospital, University of Turku, Turku, Finland

    2 shared publications
  • Anna Haanpää

    Department of Neurology Neurocenter, Helsinki University Hospital Helsinki Finland

    1 shared publication
  • Anna‐Leena Pirttisalo

    Department of Neurology Turku University Hospital Turku Finland

    1 shared publication

Latest Publications

  • Open Access

    Complication burden during status epilepticus and long-term mortality

    by Madina Nazhaeva, Charlotte Damien, Leena Kämppi, Lars Egil Roberg, Olav Monson, Nicolas Gaspard, Christoph P. Beier

  • Open Access

    Epilepsy care pathway: The Finnish model

    by Reetta Kälviäinen, Zakarya Hadj‐Allal, Jarkko Kirjavainen, Reina Roivainen, Tarja Linnankivi, Jukka Peltola, Kai Eriksson, Salla Lamusuo, Tuire Lähdesmäki, Johanna Annunen, et al.

    Objective: Integrated care pathways are essential for consistent, effective epilepsy care, offering equal access and quality regardless of socioeconomic status. They must align with the WHO Global Action Plan on Epilepsy, ensuring best practices and cost‐effective management. We describe the Finnish national epilepsy care pathway, which includes multiple levels of care, from initial diagnosis to long‐term care for all types of epilepsy, with a specific focus on rare and complex cases integrated with the European Reference Network (ERN) for Rare and Complex Epilepsies EpiCARE.Methods: In 2017, the Finnish government nominated Kuopio University Hospital to coordinate diagnostics and care for severe epilepsy in Finland. A national multidisciplinary consensus panel, including specialists from both adult and pediatric neurology departments across all five Finnish university hospitals and from the patient organization, was established. The resulting pathway was adopted into the current Finnish evidence‐based current care guidelines for epilepsy.Results: The Finnish epilepsy care pathway focuses on timely referrals, continuity of care and enhanced communication between healthcare providers at different levels of care. Patient involvement is assured with an individualized digital application offering secure online messaging, a seizure calendar, and remote visits. The pathway enhances virtual consultations and includes regular national diagnostic multidisciplinary meetings for severe epilepsies before selected cases are consulted in ERN EpiCARE meetings.Significance: This Finnish model for epilepsy care provides a streamlined, multidisciplinary approach to diagnosis and treatment and combines modern digital tools, data sharing, and peer support. This pathway can serve to model how integrated healthcare systems can effectively manage complex conditions.Plain Language Summary: We describe the Finnish national epilepsy care pathway, which includes multiple levels of care, from initial diagnosis to long‐term care for all types of epilepsy, with a specific focus on rare and complex cases integrated with the European Reference Network (ERN) for Rare and Complex Epilepsies EpiCARE. Finnish model for epilepsy care provides a streamlined, multidisciplinary approach to diagnosis and long‐term treatment of epilepsy. The pathway enhances virtual consultations and includes national and European‐level diagnostic multidisciplinary meetings for severe epilepsies. To improve outcomes, we emphasize the use of modern digital tools, data sharing, and peer support.


  • Open Access

    Combined value of interictal markers and stimulated seizures to estimate the seizure onset zone in stereoelectroencephalography

    by Lauri Rekola, Maria Peltola, Jukka Vanhanen, Juha Wilenius, Eeva‐Liisa Metsähonkala, Leena Kämppi, Leena Lauronen, Päivi Nevalainen

    Objective: This study was undertaken to investigate the potential of interictal electroencephalographic (EEG) findings and electrically stimulated seizures during stereo‐EEG (SEEG) as surrogate markers for the spontaneous seizure onset zone (spSOZ). We hypothesized that combining the localizing information of these markers would allow clinically meaningful estimation of the spSOZ.Methods: We included all patients (n = 63) who underwent SEEG between January 2013 and March 2020 at Helsinki University Hospital and had spontaneous seizures during the recording. We scored spikes, gamma activity, and background abnormality on each channel visually during a 12‐h epoch containing waking state and sleep. Based on semiology, we classified stimulated seizures as typical or atypical/unclassifiable and estimated the stimulated SOZ (stimSOZ) for typical seizures. To assess which markers increased the odds of channel inclusion in the spSOZ, we fitted mixed effects logistic regression models.Results: A combined regression model including the stimSOZ and interictal markers scored during sleep performed better in estimating which channels were part of the spSOZ than models based on stimSOZ (p < .001) or interictal markers (p < .001) alone. Of the individual markers, the effect sizes were greatest for inclusion of a channel in the stimSOZ (odds ratio [OR] = 60, 95% confidence interval [CI] = 37–97, p < .001) and for continuous (OR = 25, 95% CI = 12–55, p < .001) and subcontinuous (OR = 36, 95% CI = 21–64, p < .001) interictal spiking. At the individual level, the model's accuracy to predict spSOZ inclusion varied markedly (median accuracy = 85.7, range = 54.4–100), which was not explained by etiology (p > .05).Significance: Compared to either marker alone, combining visually rated interictal SEEG markers and stimulated seizures improved prediction of which SEEG channels belonged to the spSOZ. Inclusion in the stimSOZ and continuous or subcontinuous spikes increased the odds of spSOZ inclusion the most. Future studies should investigate whether suboptimal sampling of the true epileptogenic zone can explain the model's poor performance in certain patients.


  • Open Access

    Hemophagocytic lymphohistiocytosis in an adult patient with super‐refractory status epilepticus

    by Anna Haanpää, Leena Kämppi, Jonas Kantonen, Liisa Myllykangas, Sini M. Laakso, Nina Forss

    This case report presents a 38‐year‐old male patient who, after a febrile infection, developed super‐refractory status epilepticus and multiorgan failure, and died in 2 weeks despite the best possible intensive care. Autopsy revealed findings suggestive of hemophagocytic lymphohistiocytosis (HLH). This case shows that a rare immunological cause such as HLH may cause febrile infection‐related epilepsy syndrome (FIRES), and complications of intensive care can mask the physiological and laboratory changes in HLH.Plain Language Summary: This case report presents a 38‐year‐old man who, after a febrile infection, developed intractable epileptic activity requiring intensive care treatment. During the intensive care, the patient showed signs of multiple organ damage and died in 2 weeks despite the best possible treatment. Autopsy revealed findings suggestive of hemophagocytic lymphohistiocytosis (HLH), which is a rare immune system regulation disorder leading to persistent inflammatory state and organ damages. This case shows that an immunological disorder like HLH may underlie treatment resistant fever‐related epileptic seizures.


  • Open Access

    Clinical characteristics and outcomes of patients with recurrent status epilepticus episodes

    by Kristina Bauer, Felix Rosenow, Susanne Knake, Laurent M. Willems, Leena Kämppi, Adam Strzelczyk

    Background: Multiple studies have focused on medical and pharmacological treatments and outcome predictors of patients with status epilepticus (SE). However, a sufficient understanding of recurrent episodes of SE is lacking. Therefore, we reviewed recurrent SE episodes to investigate their clinical characteristics and outcomes in patients with relapses.Methods: In this retrospective, multicenter study, we reviewed recurrent SE patient data covering 2011 to 2017 from the university hospitals of Frankfurt and Marburg, Germany. Clinical characteristics and outcome variables were compared among the first and subsequent SE episodes using a standardized form for data collection.Results: We identified 120 recurrent SE episodes in 80 patients (10.2% of all 1177 episodes). The mean age at the first SE episode was 62.2 years (median 66.5; SD 19.3; range 21–91), and 42 of these patients were male (52.5%). A mean of 262.4 days passed between the first and the second episode. Tonic–clonic seizure semiology and a cerebrovascular disease etiology were predominant in initial and recurrent episodes. After subsequent episodes, patients showed increased disability as indicated by the modified Rankin Scale (mRS), and 9 out of 80 patients died during the second episode (11.3%). Increases in refractory and super-refractory SE (RSE and SRSE, respectively) were noted during the second episode, and the occurrence of a non-refractory SE (NRSE) during the first SE episode did not necessarily provide a protective marker for subsequent non-refractory episodes. An increase in the use of intravenous-available anti-seizure medication (ASM) was observed in the treatment of SE patients. Patients were discharged from hospital with a mean of 2.8 ± 1.0 ASMs after the second SE episode and 2.1 ± 1.2 ASMs after the first episode. Levetiracetam was the most common ASM used before admission and on discharge for SE patients.Conclusions: This retrospective, multicenter study used the mRS to demonstrate worsened outcomes of patients at consecutive SE episodes. ASM accumulations after subsequent SE episodes were registered over the study period. The study results underline the necessity for improved clinical follow-ups and outpatient care to reduce the health care burden from recurrent SE episodes.


  • Open Access

    Burden of suspected epileptic seizures on emergency services: A population‐based study

    by Leena Kämppi, Tuukka Puolakka, Jaakko Ritvanen, Kati Tuppurainen, Jari Päkkilä, Markku Kuisma, Jukka Peltola

    Background and purpose: Patients with acute epileptic seizures form a large patient group in emergency neurology. This study aims to determine the burden caused by suspected epileptic seizures at different steps in emergency care.Methods: A retrospective, cross‐sectional, population‐based (>1,000,000 inhabitants), 4‐year (2015–2018) study was conducted in an urban setting with a single dispatch centre, a university hospital‐affiliated emergency medical service (EMS), and five emergency departments (EDs). The study covered all adult (≥16 years old) emergency neurology patients receiving medical attention due to suspected epileptic seizures from the EMS and EDs and during hospital admissions in the Helsinki metropolitan area.Results: Epileptic seizures were suspected in 14,364 EMS calls, corresponding to 3.3% of all EMS calls during the study period. 9,112 (63.4%) cases were transported to hospital due to suspected epileptic seizures, and 3368 (23.4%) were discharged on the scene. 6969 individual patients had 11,493 seizure‐related ED visits, accounting for 3.1% of neurology‐ and internal medicine‐related ED visits and 4607 hospital admissions were needed with 3 days’ median length of stay (IQR=4, Range 1‐138). Male predominance was noticeable at all stages (EMS 64.7%, EDs 60.1%, hospital admissions 56.2%). The overall incidence was 333/100,000 inhabitants/year for seizure‐related EMS calls, 266/100,000 inhabitants/year for ED visits and 107/100,000 inhabitants/year for hospital admissions. Total estimated costs were 6.8 million €/year, corresponding to 0.5% of all specialized healthcare costs in the study area.Conclusions: Patients with suspected epileptic seizures cause a significant burden on the health care system. Present‐day epidemiological data are paramount when planning resource allocation in emergency services.


  • Predictors of mortality at one year after generalized convulsive status epilepticus

    by Kati Marjatta Tuppurainen, Jaakko Gabriel Ritvanen, Harri Mustonen, Leena Sinikka Kämppi


  • Complication Burden Index—A tool for comprehensive evaluation of the effect of complications on functional outcome after status epilepticus

    by Leena Kämppi, Jaakko Ritvanen, Daniel Strbian, Harri Mustonen, Seppo Soinila

    Systemic complications are common in status epilepticus. We have no tools to evaluate total burden of complications and its effect on the outcome of status epilepticus. For Complication Burden Index (CBI) a patient is assessed for 13 complication categories: respiratory, cardiovascular, nervous, renal, hepatic, coagulation, gastrointestinal and musculoskeletal systems, electrolyte/acid‐base balance, infection, hypo‐/hyperglycemia, skin/allergic reactions, and mental condition. Maximum CBI is 13. CBI was internally validated in a retrospective cohort of 70 consecutive adult patients with generalized convulsive status epilepticus (GCSE) treated in a tertiary hospital over a period of 2 years. Functional outcome at discharge was defined Poor for Glascow Outcome Scale (GOS) 1‐3 or worse‐than‐baseline condition and Good for GOS >3 or return to baseline condition. Relative risks (RRs) and receiver‐operating characteristic (ROC) ‐curves were calculated to obtain optimal cutoff. Functional outcome was poor in 40% and worse‐than‐baseline in 59%. In‐hospital mortality was 7%. Average CBI was 3.8 (range 0‐10, median 3). Cutoff value predicting poor functional outcome was a CBI >3 (GOS 1‐3 RR 1.84, P = .045, 95% confidence interval [CI 1.01‐3.33; ROC‐AUC [area under the curve] 0.687, P = .008, sensitivity 64%, specificity 61%; worse‐than‐baseline condition RR 1.52, P = .04, 95% CI 1.02‐2.26; ROC‐AUC 0.662, P = .022, sensitivity 56%, specificity 69%). CBI with cutoff >3 and as a continuous variable was associated with GOS1‐3 (P = .046, P = .002) and with worse‐than‐baseline condition (P = .041, P = .004). CBI is a novel tool for comprehensive assessment of status epilepticus complications predicting poor/worse‐than‐baseline functional outcome with cutoff >3.